|
|
|
Insider
Information: |
Tessier-Lavigne Marc |
Relationship: |
Director |
City: |
So San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
2,234,086 |
|
Indirect Shares
|
236,869 |
|
|
Direct
Value |
$45,964,833 |
|
|
Indirect Value
|
$4,910,294 |
|
|
Total
Shares |
2,470,955 |
|
|
Total
Value |
$50,875,128 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
9
|
Stock
price went up :
|
0
|
3
|
Stock
price went down : |
0
|
6
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
42.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Pfizer Inc |
PFE |
Director |
2011-12-12 |
104 |
|
0 |
Premium* |
|
Regeneron Pharmaceuticals Inc |
REGN |
Director |
2023-01-03 |
2,434 |
2013-05-06 |
0 |
Premium* |
|
Agios Pharmaceuticals Inc |
AGIO |
Director |
2013-07-24 |
101,009 |
|
0 |
Premium* |
|
Juno Therapeutics, Inc. |
JUNO |
Director |
2014-12-23 |
250,000 |
|
0 |
Premium* |
|
Denali Therapeutics Inc. |
DNLI |
Director |
2024-05-31 |
1,880,539 |
2024-05-31 |
236,869 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
66 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
JUNO |
Juno Therapeutics, Inc. |
Director |
|
2014-12-23 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
250,000 |
0 |
- |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2017-12-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
3,139,043 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2019-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
323 |
1,510 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
320 |
1,830 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2021-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
248 |
2,078 |
0 |
- |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
2,544,370 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
191 |
2,269 |
0 |
- |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
5,986 |
2,030,356 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
165 |
2,434 |
0 |
- |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,216 |
1,874,572 |
0 |
- |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2024-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,967 |
1,880,539 |
0 |
- |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2021-03-01 |
4 |
AS |
$64.36 |
$6,622,207 |
D/D |
(100,000) |
2,642,296 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2021-05-03 |
4 |
AS |
$60.08 |
$194,589 |
D/D |
(3,237) |
2,589,059 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2021-05-21 |
4 |
AS |
$60.13 |
$2,282,468 |
D/D |
(37,957) |
2,551,102 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2021-05-24 |
4 |
AS |
$60.03 |
$528,580 |
D/D |
(8,806) |
2,542,296 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2021-06-07 |
4 |
AS |
$70.35 |
$6,639,523 |
D/D |
(94,378) |
2,544,370 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2021-09-13 |
4 |
AS |
$636.64 |
$8,181,827 |
D/D |
(12,750) |
2,078 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2021-12-09 |
4 |
AS |
$665.00 |
$2,516,360 |
D/D |
(3,784) |
2,078 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2022-03-16 |
4 |
AS |
$675.00 |
$2,943,675 |
D/D |
(4,361) |
2,269 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2022-03-17 |
4 |
AS |
$680.00 |
$5,324,400 |
D/D |
(7,830) |
2,269 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2022-03-21 |
4 |
AS |
$690.00 |
$5,132,910 |
D/D |
(7,439) |
2,269 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2022-08-23 |
4 |
AS |
$31.61 |
$632,282 |
D/D |
(20,000) |
1,930,356 |
0 |
% |
|
DNLI |
Denali Therapeutics Inc. |
Director |
|
2022-09-28 |
4 |
AS |
$30.74 |
$616,304 |
D/D |
(20,000) |
1,910,356 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2022-09-29 |
4 |
AS |
$686.89 |
$2,624,684 |
D/D |
(3,798) |
2,269 |
0 |
% |
|
REGN |
Regeneron Pharmaceuticals... |
Director |
|
2022-09-30 |
4 |
AS |
$698.00 |
$2,392,744 |
D/D |
(3,428) |
2,269 |
0 |
% |
|
66 Records found
|
|
Page 1 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|